AlzBiomarker
Control vs Alzheimer's Disease: Aβ42 (Plasma and Serum)
Meta-analysis of 51 comparisons showed that levels of Aβ42 in blood—plasma or serum—were not significantly different between controls and people with Alzheimer’s disease (effect size 0.959, p = 0.058). However, the Aβ42:Aβ40 ratio has gained attention as a plasma biomarker that predicts amyloid-PET status regardless of clinical diagnosis (Doecke et al., 2020; Pérez-Grijalba et al., 2019).
Loading data...